Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 22Prostatic Neoplasms 21Glioblastoma 19Lung Neoplasms 17Squamous Cell Carcinoma of Head and Neck 16Rectal Neoplasms 12Glioma 12Neoplasms 11Oropharyngeal Neoplasms 10Head and Neck Neoplasms 10Esophageal Neoplasms 8Astrocytoma 8Sarcoma 7Neoplasm Metastasis 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Esophageal Squamous Cell Carcinoma 6Colorectal Neoplasms 6Carcinoma, Squamous Cell 6Brain Neoplasms 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Lymphoma, Follicular 5Hodgkin Disease 5Gliosarcoma 5Carcinoma, Hepatocellular 5Carcinoma 5Burkitt Lymphoma 5

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Radiotherapy × 90 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡